Adjuvant Targeted Therapy Proves Beneficial in Resected Stage III BRAF-Mutant Melanoma
Source: Targeted Oncology, June 2021
Targeted therapy use in melanoma has been extended beyond just metastatic disease to now include adjuvant therapy for patients with resected stage III melanoma.
Adjuvant targeted therapy use in melanoma has had the most impact thus far on BRAF-mutant disease, as approximately 35% to 40% of melanoma cases are BRAF mutant.
